The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CALA | -90% | -100% | -93.28% | -100% |
| S&P | +15.06% | +95.03% | +14.29% | +242% |
Calithera Biosciences, Inc. is a clinical stage precision oncology biopharmaceutical company, which engages in developing targeted therapies to redefine treatment for biomarker-specific patient populations. It also focuses on researching small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.
The company reported negative results from a clinical trial.
The tiny pharma stock received an upgrade from a prominent analyst.
Currently no data to display
Currently no data to display.
Currently no data to display.
| Metric | YoY Change |
|---|
CALA earnings call for the period ending June 30, 2022.
CALA earnings call for the period ending March 31, 2022.
CALA earnings call for the period ending December 31, 2021.
CALA earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
